Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Celecoxib

Hazard - P - B - T - Risk Låg

Information

Environmental information is missing on fass.se (2019-11-06). It is voluntary for manufacturers to provide information about environmental impact on fass.se.

Scientific discussion for the approval of Onsenal (celecoxib)

Onsenal is no longer authorised. "This scientific discussion has been updated until 1 May 2004. No particular risks to the environment of celecoxib use in FAP (familial adenomatous polyposis, red note) can be foreseen.

Report Goodpoint 2019

Comparative assessment of environmental risk when using diclofenac, naproxen, ibuprofen, ketoprofen, etoricoxib, celecoxib and paracetamol from a Swedish perspective (Report Goodpoint 2019). From an environmental risk point of view, the exchange of diclofenac is recommended for any of the other investigated NSAIDs/analgesics. [...] Paracetamol is a very safe alternative from an environmental point of view. The others are also considered to pose low environmental risk, but slightly increased for ketoprofen. The risk factors for ketoprofen, naproxen, ibuprofen, celecoxib, etoricoxib and paracetamol are not considered so great that an exchange with another substance is recommended. Environmental measurements as well as efficacy studies of both celecoxib and etoricoxib are required."

References

  1. European Medicines Agency. European public assessment reports (EPAR).
  2. Goodpoint. Jämförande bedömning av miljörisk vid användning av diklofenak, naproxen, ibuprofen, ketoprofen, etoricoxib, celecoxib samt paracetamol. Stockholm; Goodpoint; 2019.

Author: Health and Medical Care Administration, Region Stockholm